Compare TLSA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLSA | PSNL |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.2M | 729.1M |
| IPO Year | 2017 | 2019 |
| Metric | TLSA | PSNL |
|---|---|---|
| Price | $1.24 | $6.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 136.4K | ★ 1.5M |
| Earning Date | 05-06-2025 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.47 |
| Revenue Next Year | N/A | $39.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $2.83 |
| 52 Week High | $2.60 | $11.50 |
| Indicator | TLSA | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 38.41 |
| Support Level | N/A | $4.65 |
| Resistance Level | $1.62 | $6.94 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 32.14 | 22.40 |
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.